• Cube Labs’ 51%-owned Cartilago secured European patent EP 3853238 for a glucosamine-derived cream targeting skin aging.
• The patent covers topical cosmetic formulations containing 0.1%-2% NAPA, which stimulated collagen production in preclinical studies.
• Cartilago plans unitary patent protection in participating countries, with additional validation in the UK, Switzerland and Spain.
• New platform Serescentia will consolidate high-potential businesses and commercialize innovative health and wellness products, supporting the group’s longevity strategy.
• Three potential acquisition targets are already under evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cube Labs S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20282-34-2026_TELEBORSA.pdf), on November 04, 2026, and is solely responsible for the information contained therein.